Mind the gap? The platform trial as a working environment.

Adaptive design Biomarker Compassion Efficiency Platform trial Precision medicine Qualitative Researcher Stratified medicine Trial management

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
29 May 2019
Historique:
received: 10 12 2018
accepted: 19 04 2019
entrez: 30 5 2019
pubmed: 30 5 2019
medline: 24 12 2019
Statut: epublish

Résumé

Trials have become bigger and more complicated due to the complexity introduced by biomarker stratification, and the advent of multi-arm multi-stage trials, and umbrella and basket platform designs. The trials unit at University College London has been at the forefront of this work, with ground-breaking trials such as STAMPEDE and FOCUS4. The trial management and data management teams on these trials have summarised the operational challenges, to enable the broader clinical trials community to learn from their experiences. In a small-scale qualitative study, we examined the personal experience of individual researchers working on these trials. We found reports of high workloads, with potentially significant stress for individuals and with an impact on their career choices. We conclude that there was an initial underestimation of the work required and of the inherent, largely unanticipated, challenges. We discuss the importance of fully understanding these trials' resource requirements, both for those writing grant applications and critically, for those with responsibility for deciding on funding. The working environment was characterised by three features: complexity, scale and heightened expectations. These features are highly attractive for professional development and engender high levels of loyalty and commitment. We observed a trade-off between these intrinsic rewards and the continuous demands of overlapping tasks, balancing a mix of routine and high-profile work, and the changing nature of pivotal roles. Such demands present challenges for colleague relationships, by enhancing the potential for competition and by disrupting the natural opportunities to pause, review and celebrate team achievements. In addition, molecular stratification in effect brings the patient into the trial office, as a specific individual, despite anonymisation, who is owed test results and a treatment decision. We discuss these observations with a view to interconnecting the need for compassion for patients with caring for the researchers engaged in the research ecosystem who are aiming to produce much hoped-for advances in medical science. There is a need for increased awareness of the challenge these studies place on those throughout the team delivering the study. Such considerations must influence leaders and funders, both in their initial budget considerations and throughout delivery.

Sections du résumé

BACKGROUND BACKGROUND
Trials have become bigger and more complicated due to the complexity introduced by biomarker stratification, and the advent of multi-arm multi-stage trials, and umbrella and basket platform designs. The trials unit at University College London has been at the forefront of this work, with ground-breaking trials such as STAMPEDE and FOCUS4. The trial management and data management teams on these trials have summarised the operational challenges, to enable the broader clinical trials community to learn from their experiences. In a small-scale qualitative study, we examined the personal experience of individual researchers working on these trials.
COMMENTARY CONCLUSIONS
We found reports of high workloads, with potentially significant stress for individuals and with an impact on their career choices. We conclude that there was an initial underestimation of the work required and of the inherent, largely unanticipated, challenges. We discuss the importance of fully understanding these trials' resource requirements, both for those writing grant applications and critically, for those with responsibility for deciding on funding. The working environment was characterised by three features: complexity, scale and heightened expectations. These features are highly attractive for professional development and engender high levels of loyalty and commitment. We observed a trade-off between these intrinsic rewards and the continuous demands of overlapping tasks, balancing a mix of routine and high-profile work, and the changing nature of pivotal roles. Such demands present challenges for colleague relationships, by enhancing the potential for competition and by disrupting the natural opportunities to pause, review and celebrate team achievements. In addition, molecular stratification in effect brings the patient into the trial office, as a specific individual, despite anonymisation, who is owed test results and a treatment decision. We discuss these observations with a view to interconnecting the need for compassion for patients with caring for the researchers engaged in the research ecosystem who are aiming to produce much hoped-for advances in medical science.
CONCLUSIONS CONCLUSIONS
There is a need for increased awareness of the challenge these studies place on those throughout the team delivering the study. Such considerations must influence leaders and funders, both in their initial budget considerations and throughout delivery.

Identifiants

pubmed: 31138284
doi: 10.1186/s13063-019-3377-5
pii: 10.1186/s13063-019-3377-5
pmc: PMC6540560
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

297

Subventions

Organisme : Department of Health
ID : 11/100/50
Pays : United Kingdom
Organisme : Arts and Humanities Research Council
ID : AH/N009770/1
Organisme : Medical Research Council
ID : MC_UU_12023/20
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/24
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 3804
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M016587/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/25
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/4
Pays : United Kingdom

Références

Biomed Hub. 2017 Nov;2(Suppl 1):
pubmed: 30613576
J Occup Health Psychol. 1996 Jan;1(1):27-41
pubmed: 9547031
N Engl J Med. 2017 Jul 6;377(1):62-70
pubmed: 28679092
Trials. 2019 May 29;20(1):294
pubmed: 31138292
New Bioeth. 2017 Apr;23(1):1-12
pubmed: 28517985
Clin Trials. 2017 Oct;14(5):451-461
pubmed: 28830236
Trials. 2012 Sep 15;13:168
pubmed: 22978443
New Bioeth. 2017 Apr;23(1):55-63
pubmed: 28517991
Trials. 2019 May 29;20(1):264
pubmed: 31138317
Lancet. 2014 Jul 26;384(9940):283-4
pubmed: 25066148

Auteurs

Liz Morrell (L)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK. liz.morrell@ndph.ox.ac.uk.

Joshua Hordern (J)

Oxford Healthcare Values Partnership, Faculty of Theology and Religion, and Harris Manchester College, University of Oxford, Oxford, UK.

Louise Brown (L)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.

Matthew R Sydes (MR)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.

Claire L Amos (CL)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.

Richard S Kaplan (RS)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.

Mahesh K B Parmar (MKB)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.

Timothy S Maughan (TS)

CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Oxford University Hospital Foundation Trust, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH